vix.ing · top · new · best · stats · spec

Using Reinforcement Learning to Simplify Mealtime Insulin Dosing for People with Type 1 Diabetes: In-Silico Experiments

2023/09/17 by Anas El Fathi, Fathi, Anas El, Marc D. Breton +1 · 1 citation
Biochemistry, Genetics and Molecular Biology · Medicine · #Artificial Intelligence (cs.AI) #FOS: Computer and information sciences #Pancreatic function and diabetes #Receptor Mechanisms and Signaling

paper · pdf · doi:10.48550/arxiv.2309.09125

openalex publication_date 2023/09/17 · openalex created_date 2023/09/20 · openalex updated_date 2026/07/28

Abstract

People with type 1 diabetes (T1D) struggle to calculate the optimal insulin dose at mealtime, especially when under multiple daily injections (MDI) therapy. Effectively, they will not always perform rigorous and precise calculations, but occasionally, they might rely on intuition and previous experience. Reinforcement learning (RL) has shown outstanding results in outperforming humans on tasks requiring intuition and learning from experience. In this work, we propose an RL agent that recommends the optimal meal-accompanying insulin dose corresponding to a qualitative meal (QM) strategy that does not require precise carbohydrate counting (CC) (e.g., a usual meal at noon.). The agent is trained using the soft actor-critic approach and comprises long short-term memory (LSTM) neurons. For training, eighty virtual subjects (VS) of the FDA-accepted UVA/Padova T1D adult population were simulated using MDI therapy and QM strategy. For validation, the remaining twenty VS were examined in 26-week scenarios, including intra- and inter-day variabilities in glucose. In-silico results showed that the proposed RL approach outperforms a baseline run-to-run approach and can replace the standard CC approach. Specifically, after 26 weeks, the time-in-range (70-180mg/dL) and time-in-hypoglycemia (<70mg/dL) were 73.1±11.6% and 2.0± 1.8% using the RL-optimized QM strategy compared to 70.6±14.8% and 1.5± 1.5% using CC. Such an approach can simplify diabetes treatment, resulting in improved quality of life and glycemic outcomes.

Cited by

Related